This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Biocept Valuation

Is B00 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of B00 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate B00's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate B00's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for B00?

Key metric: As B00 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for B00. This is calculated by dividing B00's market cap by their current revenue.
What is B00's PS Ratio?
PS Ratio	0.2x
Sales	US$6.59m
Market Cap	US$1.62m

B00 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1x
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does B00's PS Ratio compare to its peers?

The above table shows the PS ratio for B00 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.3x
PA8 Paion	0.2x	30.2%	€2.6m
SBH Sangui Biotech International	3.8x	n/a	€419.8k
CNW co.don	0.7x	n/a	€6.5m
BPXA Bellicum Pharmaceuticals	0.5x	n/a	€772.4k
B00 Biocept	0.2x	53.1%	€1.6m

Price-To-Sales vs Peers: B00 is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (8.1x).

Price to Sales Ratio vs Industry

How does B00's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.1x	21.8%
B00 Biocept	0.2x	53.1%	US$1.62m
CNW co.don	0.7x	n/a	US$6.97m
V9Z Aceragen	0.4x	n/a	US$3.12m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	8.1x	42.4%
B00 Biocept	0.2x	65.8%	US$1.62m

No more companies

Price-To-Sales vs Industry: B00 is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is B00's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

B00 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	0.3x

Price-To-Sales vs Fair Ratio: B00 is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

-1.6%

-38.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

-1.8%

0.2%